Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib plus platinum-pemetrexed versus chemotherapy alone in first-line EGFR exon 20 insertion advanced NSCLC
NL-OMON60575Phase 3Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Taiho Oncology. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival by blinded independent central review. Started Feb 2024; status: active, not recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60575.